Lawrence Einhorn

Q: What Schools Are Affiliated With Lawrence Einhorn

Lawrence Einhorn is affiliated with the following schools: Indiana University Bloomington, Indiana University, Indiana University–Purdue University Indianapolis, Purdue University, University of Iowa, University of Washington

Lawrence Einhorn's AcademicInfluence.com Rankings

Lawrence Einhorn

Philosophy

#2791

World Rank

#4660

Historical Rank

#954

USA Rank

Logic

#941

World Rank

#1532

Historical Rank

#319

USA Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Lawrence Einhorn Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Lawrence Einhorn is an American oncologist at Indiana University School of Medicine. A pioneer in cancer treatment research, Einhorn developed cisplatin-based chemotherapy regimens that increased cure rates while minimizing toxic side effects.

(See a Problem?)

Lawrence Einhorn's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. (2004) (2399)
Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. (1977) (1487)
Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. (1987) (1112)
Recommendations on the Use of 18F-FDG PET in Oncology (2008) (766)
Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. (2000) (734)
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. (1999) (729)
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. (1992) (710)
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. (2010) (655)
Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. (2001) (618)
A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. (1992) (582)
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. (2006) (499)
Treatment of testicular cancer: a new and improved model. (1990) (488)
Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. (1997) (486)
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. (2008) (432)
High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. (2007) (411)
Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. (2002) (398)
Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. (1998) (364)
Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. (1981) (353)
Curing metastatic testicular cancer (2002) (339)
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. (2016) (337)
Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. (1989) (334)
The development of non‐germ cell malignancies within germ cell tumors. A clinicopathologic study of 11 cases (1984) (332)
Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. (2007) (302)
Long term effect of Cis‐Diamminedichloride platinum (CDDP) on renal function and structure in man (1978) (298)
High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. (1996) (296)
Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. (1998) (290)
Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. (2006) (288)
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. (1987) (287)
Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells (2000) (282)
Testicular cancer survivorship: research strategies and recommendations. (2010) (264)
Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. (1991) (263)
Prognostic factors for favorable outcome in disseminated germ cell tumors. (1986) (258)
Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. (1994) (253)
Testicular cancer--discoveries and updates. (2014) (246)
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. (2010) (243)
Late relapse of testicular cancer. (1995) (237)
Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. (1988) (236)
Chemotherapy of disseminated testicular cancer a random prospective study (1980) (228)
Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. (1974) (225)
American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. (2010) (224)
Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. (1995) (218)
Cisplatin as first-line therapy for metastatic breast cancer. (1988) (218)
Fertility after chemotherapy for testicular cancer. (1983) (212)
Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. (1997) (210)
The role of maintenance therapy in disseminated testicular cancer. (1981) (209)
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. (2005) (208)
Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. (1999) (207)
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. (2011) (201)
Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. (1993) (199)
Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report. (1984) (198)
Surgical salvage of chemorefractory germ cell tumors. (1993) (197)
Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. (1993) (195)
Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. (1979) (194)
Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. (2001) (194)
Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction (1981) (192)
Klinefelter's syndrome associated with mediastinal germ cell neoplasms. (1987) (185)
Hematologic malignancies associated with primary mediastinal germ-cell tumors. (1985) (182)
Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin. (1974) (175)
Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. (1987) (172)
Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. (1998) (171)
Update on late relapse of germ cell tumor: a clinical and molecular analysis. (2003) (168)
Improved chemotherapy in disseminated testicular cancer. (1977) (166)
Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. (1988) (165)
VP‐16–213 salvage therapy for refractory germinal neoplasms (1980) (164)
Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. (2000) (162)
Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. (1996) (162)
Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. (1992) (160)
Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. (2016) (160)
The role of cis-platinum in solid-tumor therapy. (1979) (158)
Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. (2003) (156)
Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. (1995) (155)
VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. (1986) (155)
Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer (1976) (155)
Metastatic patterns of choroidal melanoma (1974) (154)
The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). (1995) (153)
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. (1999) (153)
Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. (2006) (152)
Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. (2001) (151)
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group (2010) (149)
Advanced extragonadal germ-cell tumors. Successful treatment with combination chemotherapy. (1982) (148)
Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors (2003) (143)
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? (2016) (141)
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study (2007) (138)
High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. (2000) (138)
Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? (2010) (137)
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study (2005) (134)
Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial. (1985) (134)
Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. (1997) (133)
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. (2006) (133)
Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors: a clinicopathological correlation. (1986) (133)
A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. (1987) (128)
Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. (1986) (128)
Active surveillance is the preferred approach to clinical stage I testicular cancer. (2013) (123)
Ifosfamide in refractory male germ cell tumors. (1986) (122)
Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged ≥70 Years or with Poor Performance Status (CheckMate 153). (2019) (122)
Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease. (1994) (121)
Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. (1997) (120)
Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. (1986) (120)
A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors. (2008) (120)
Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. (1987) (120)
Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. (1989) (120)
Primary mediastinal nonseminomatous germ cell tumors. A modern single institution experience (1990) (116)
Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206 (2018) (116)
Long-term results in combined-modality treatment of small cell carcinoma of the lung. (1978) (111)
Testicular cancer: a reflection on 50 years of discovery. (2014) (111)
Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma--predominant testis cancer. (2000) (108)
Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? (2007) (108)
High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience. (2017) (108)
Phase II study of daily oral etoposide in refractory germ cell tumors. (1990) (108)
Extragonadal germ cell tumors: clinical presentation and management (2013) (104)
Phase II Study of Imatinib Mesylate in Chemotherapy Refractory Germ Cell Tumors Expressing KIT (2006) (104)
Primary mediastinal nonseminomatous germ cell tumors. Results of a multimodality approach. (1990) (104)
Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. (2002) (104)
Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report. (1979) (103)
Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. (2002) (102)
Primary mediastinal nonseminomatous germ cell tumors: the influence of postchemotherapy pathology on long-term survival after surgery. (1999) (101)
Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience. (1994) (100)
Endodermal sinus tumor of the mediastinum (1982) (100)
Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy (2005) (99)
Is prophylactic cranial irradiation indicated in small-cell lung cancer? (1990) (99)
Somatic mutations of KIT in familial testicular germ cell tumours (2004) (98)
Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin. (1995) (98)
Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. (2006) (98)
Testicular cancer: the quest continues. (1988) (97)
Cytoreductive surgery for metastatic testis cancer: considerations of timing and extent. (1980) (97)
Assessment of quality of life in outpatients with advanced cancer: the accuracy of clinician estimations and the relevance of spiritual well-being--a Hoosier Oncology Group Study. (2003) (96)
Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. (2005) (95)
Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. (2001) (95)
Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. (1994) (95)
Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. (1991) (94)
Small cell lung cancer: progress and perspectives. (1978) (93)
Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. (2014) (92)
Endoscopic ultrasound in non-small cell lung cancer and negative mediastinum on computed tomography. (2005) (92)
Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. (1999) (92)
Combination chemotherapy in disseminated testicular cancer: the Indiana University experience. (1979) (92)
Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. (1998) (92)
Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. (2000) (91)
Cytoreductive surgery for metastatic testis cancer: tissue analysis of retroperitoneal masses after chemotherapy. (1982) (91)
Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. (2007) (91)
Perceptions of masculinity and self‐image in adolescent and young adult testicular cancer survivors: implications for romantic and sexual relationships (2011) (91)
Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer (2007) (89)
Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. (2005) (87)
Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer (1997) (86)
Chemotherapy of disseminated testicular cancer. (1979) (82)
Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier on (2012) (82)
Accuracy of preoperative staging in stages A and B nonseminomatous germ cell testis tumors. (1982) (81)
1297ORandomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC) (2017) (79)
Nabilone: An Effective Antiemetic in Patients Receiving Cancer Chemotherapy (1981) (78)
Does retroperitoneal lymph node dissection have a curative role for patients with sex cord–stromal testicular tumors? (2003) (78)
Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures. (2005) (78)
Angiosarcoma associated with germ cell tumors. (1985) (78)
Redox Regulation of the Embryonic Stem Cell Transcription Factor Oct‐4 by Thioredoxin (2004) (77)
Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. (2003) (77)
Late relapse of clinical stage I testicular cancer. (1995) (77)
Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. (1994) (74)
A phase II study of methylphenidate for the treatment of fatigue (2006) (74)
Serum alpha-fetoprotein and human chorionic gonadotropin in patients with seminoma. (1980) (73)
Delayed emesis: moderately emetogenic chemotherapy (2005) (72)
Chemotherapy of disseminated seminoma. (1980) (72)
Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial. (1990) (72)
Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. (1990) (72)
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153 (2020) (72)
Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. (2015) (72)
Long-term toxicity of cisplatin in germ-cell tumor survivors. (2017) (71)
Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy. (2017) (71)
Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers (2016) (71)
Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors (2000) (70)
Combination chemoimmunotherapy of metastatic breast cancer with 5‐fluorouracil, adriamycin, cyclophosphamide, and BCG (1979) (70)
Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. (1996) (70)
High dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors. (1991) (69)
Immediate Adjuvant Chemotherapy Versus Observation With Treatment at Relapse in Pathological Stage II Testicular Cancer (1988) (68)
Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. (1997) (68)
Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. (2018) (68)
Long-term toxicity of cisplatin in germ-cell tumor survivors (2017) (67)
Phase III double‐blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple‐day cisplatin‐based chemotherapy (1992) (67)
Brain metastases and testicular tumors: long-term survival. (1992) (66)
Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. (2000) (66)
Management of germ cell tumors with somatic type malignancy: pathological features, prognostic factors and survival outcomes. (2014) (65)
Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors (2018) (64)
COMB (cyclophosphamide, oncovin, methyl‐ccnu, and bleomycin): A four‐drug combination in solid tumors (1975) (64)
Randomized Pilot Trial of a Telephone Symptom Management Intervention for Symptomatic Lung Cancer Patients and Their Family Caregivers. (2016) (63)
2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting (2016) (63)
Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. (2003) (63)
Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group. (2016) (63)
Brain metastases in disseminated germinal neoplasms. Incidence and clinical course (1979) (62)
Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support (1994) (62)
Treatment of advanced epithelial ovarian cancer using cisplatin, adriamycin and cytoxan--the Indiana University experience. (1983) (62)
Etoposide salvage therapy for refractory germ cell tumors: an update. (1982) (62)
Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity (2016) (60)
Oat cell carcinoma of the lung. Early treatment results of combination radiation therapy and chemotherapy (1976) (59)
Teratoma in the Orchiectomy Specimen and Volume of Metastasis are Predictors of Retroperitoneal Teratoma in Post-Chemotherapy Nonseminomatous Testis Cancer (1996) (59)
Hepatic Resection of Metastatic Testicular Carcinoma: A Further Update (1999) (59)
Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels. (1998) (59)
Pathologic findings at orchiectomy following chemotherapy for disseminated testicular cancer. (1984) (58)
Primitive neuroectodermal tumors in patients with testicular germ cell tumors usually resemble pediatric-type central nervous system embryonal neoplasms and lack chromosome 22 rearrangements (2010) (58)
Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. (2002) (58)
First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology? (2008) (58)
Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine (2016) (57)
Chemotherapy for advanced thymoma. Preliminary results of an intergroup study. (1990) (57)
Gene Expression Profiling of Early- and Late-Relapse Nonseminomatous Germ Cell Tumor and Primitive Neuroectodermal Tumor of the Testis (2004) (56)
Germ cell tumor associated primitive neuroectodermal tumors. (2001) (55)
Salvage therapy with high‐dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors (1991) (55)
Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01–24/USO-023 (2007) (54)
Support service use and interest in support services among distressed family caregivers of lung cancer patients (2013) (54)
Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. (1993) (54)
Economic and social changes among distressed family caregivers of lung cancer patients (2013) (54)
Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas. (1985) (54)
Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer (2017) (53)
“Somatic-type” Malignancies Arising From Testicular Germ Cell Tumors: A Clinicopathologic Study of 124 Cases With Emphasis on Glandular Tumors Supporting Frequent Yolk Sac Tumor Origin (2014) (53)
The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers. (1996) (53)
No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study. (1992) (53)
Improved management of non-seminomatous testis tumors. (1979) (52)
The significance of atypia within teratomatous metastases after chemotherapy for malignant germ cell tumors (1987) (52)
Management of stage I testicular germ cell tumours (2016) (51)
Extraskeletal Ewing's sarcoma: Histologic and ultrastructural observations in three cases (1979) (51)
Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment. (2005) (50)
Improvements in fluorouracil chemotherapy? (1989) (50)
Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor. (2010) (50)
The importance of one-stage median sternotomy and retroperitoneal node dissection in disseminated testicular cancer. (1983) (49)
Chemotherapy for head and neck cancer. Comparison of cisplatin + vinblastine + bleomycin versus methotrexate (1986) (49)
Is retroperitoneal lymph node dissection necessary for adult paratesticular rhabdomyosarcoma? (1998) (49)
Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience. (2000) (49)
Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer. (2006) (48)
Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. (1998) (48)
Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group (2010) (47)
Bacon (bleomycin, adriamycin, CCNU, oncovin and nitrogen mustard) in squamous lung cancer. Experience in fifty patients (1976) (47)
Cisplatin plus etoposide in small cell lung cancer. (1988) (46)
The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. (2010) (46)
A retrospective analysis of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation therapy followed by surgery or surgery alone. (2005) (46)
Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors. (2006) (46)
Testicular cancer update. (2017) (45)
Mediastinal metastases from testicular nonseminomatous germ cell tumors: patterns of dissemination and predictors of long-term survival with surgery. (2003) (45)
Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors. (1995) (44)
Vinblastine, ifosfamide, and gallium nitrate—an active new regimen in patients with advanced carcinoma of the urothelium (1997) (44)
Acceptance and Commitment Therapy for Symptom Interference in Advanced Lung Cancer and Caregiver Distress: A Pilot Randomized Trial. (2019) (44)
Barriers to mental health service use and preferences for addressing emotional concerns among lung cancer patients (2014) (44)
Long-term complications of cisplatin-based chemotherapy for testis cancer. (1988) (44)
Brain metastases and testicular tumors: need for aggressive therapy. (1984) (43)
Histology in mixed germ cell tumors. Is there a favorite pairing? (2004) (43)
Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer. (2002) (43)
Utilization of sperm banking and barriers to its use in testicular cancer patients (2015) (43)
Surgical salvage therapy for malignant intrathoracic metastases from nonseminomatous germ cell cancer of testicular origin: analysis of a single-institution experience. (2005) (42)
Combined post-chemotherapy retroperitoneal lymph node dissection and resection of chest tumor under the same anesthetic is appropriate based on morbidity and tumor pathology. (1998) (42)
A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors (2013) (42)
Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer: a Hoosier Oncology Group study. (1997) (42)
Relationship between steroid receptors and response to endocrine therapy and cytotoxic chemotherapy in metastatic breast cancer (1980) (41)
Relation of proliferative activity to survival in patients with advanced germ cell cancer. (1988) (41)
Positron emission tomography scans in postchemotherapy seminoma patients with residual masses: a retrospective review from Indiana University Hospital. (2006) (41)
A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. (2002) (41)
Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014. (2016) (40)
Serum tumor markers in testicular cancer. (2013) (40)
Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases. (2008) (40)
Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors (2008) (39)
Extragonadal germ cell tumors: relation to testicular neoplasia and management options (2003) (39)
Gallium nitrate in the treatment of bladder cancer. (2003) (39)
Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer. (2019) (39)
Chemotherapeutic and surgical strategies for germ cell tumors. (2002) (39)
Initial therapy with cisplatin plus VP-16 in small-cell lung cancer. (1986) (38)
Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy (2011) (38)
Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement (2005) (37)
Tandem autotransplantation for the treatment of metastatic breast cancer. (1995) (37)
The "growing teratoma syndrome" in primary mediastinal nonseminomatous germ cell tumors: criteria based on current practice. (2012) (37)
Salvage chemotherapy for recurrent germ cell cancer. (1994) (37)
A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study. (1999) (37)
Outcome of patients with residual germ cell or non-germ cell malignancy after resection of primary mediastinal nonseminomatous germ cell cancer. (2004) (36)
Advanced testicular cancer: update for urologists. (1998) (36)
The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors (2000) (36)
Survival after resection for metastatic testicular nonseminomatous germ cell cancer to the lung or mediastinum. (2011) (36)
Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer. (1986) (34)
Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination Chemotherapy (2015) (34)
Intra‐arterial infusion therapy with 5‐(3,3‐dimeth yl‐1‐triazeno) imidazole‐4‐carboxamide (NSC 45388) for malignant melanoma (1973) (33)
Bleomycin, etoposide, and cisplatin for three cycles compared with etoposide and cisplatin for four cycles in good-risk germ cell tumors: is there a preferred regimen? (2006) (33)
Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial. (1995) (33)
Primary choriocarcinoma of the bladder with the detection of isochromosome 12p. (2002) (33)
Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer. (2005) (33)
Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors. (1995) (32)
Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group Trial. (2000) (32)
Multicenter Phase II trial of etoposide in refractory small cell lung cancer. (1985) (32)
Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement (2011) (31)
Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. (1995) (31)
Aggressive surgical management of testicular carcinoma metastatic to lungs and mediastinum. (1980) (31)
Phase II evaluation of cisplatin in advanced hepatocellular carcinoma and cholangiocarcinoma: a Southeastern Cancer Study Group Trial. (1986) (31)
Nabilone: an effective antiemetic agent in patients receiving cancer chemotherapy. (1982) (31)
Salvage therapy for germ cell tumors. (1994) (30)
Review of delayed orchiectomy in patients with disseminated testis tumors. (1983) (30)
Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors. (2020) (30)
Is retroperitoneal histology predictive of liver histology at concurrent post-chemotherapy retroperitoneal lymph node dissection and hepatic resection? (2006) (30)
Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases. (2018) (29)
A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors (1997) (29)
Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem-cell transplantation using high-dose etoposide. (2004) (29)
The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. (2012) (28)
Etoposide, Ifosfamide, and Cisplatin in Extensive Small Cell Lung Cancer (1992) (28)
Perioperative Morbidity and Mortality Associated With Bleomycin in Primary Mediastinal Nonseminomatous Germ Cell Tumor. (2016) (28)
cis-Platinum combination chemotherapy of bladder cancer: an update. (1979) (28)
Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. (2000) (27)
Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon. (1985) (27)
Detection of germ cell tumor cells in apheresis products using polymerase chain reaction. (1998) (27)
Metastatic Malignant Transformation of Teratoma to Primitive Neuroectodermal Tumor (PNET): Results With PNET-based Chemotherapy (2015) (27)
Gefitinib Plus Celecoxib in Chemotherapy-Naïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: A Phase II Study from the Hoosier Oncology Group (2008) (26)
Ifosfamide plus N-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial. (1986) (26)
Vindesine: an effective agent in the treatment of non-small cell lung cancer. (1982) (26)
Multimodality treatment of germ cell tumors of the mediastinum. (2009) (26)
PL-5 A phase III study of pemetrexed vs. docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) who were previously treated with chemotherapy (2003) (25)
HER-2/neu expression in germ cell tumours (2002) (25)
Outcome following resection for patients with primary mediastinal nonseminomatous germ-cell tumors and rising serum tumor markers post-chemotherapy. (2010) (25)
Chemotherapy of disseminated germ cell tumors (1987) (25)
Cardiac arrest due to hyperkalemia following therapy for acute lymphoblastic leukemia (1977) (25)
A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. (2002) (25)
Lymphomatoid granulomatosis: Successful treatment with CHOP combination chemotherapy (1984) (24)
5-Azacytidine (NSC 102816) in refractory germ cell tumors (1993) (24)
Combination chemotherapy of disseminated testicular carcinoma with cis platinum, diammine dichloride (CPDD), vinblastine (VLB), and bleomycin (BLEO) (1976) (24)
Review of Cannabinoids and their Antiemetic Effectiveness (1983) (24)
Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin‐based Chemotherapy: Application of the Framingham Risk Score (2018) (24)
Chemotherapy for disseminated testicular cancer. (1977) (24)
Antitumor activity of brentuximab vedotin in CD30 positive refractory germ cell tumors. (2013) (23)
Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors. (2018) (23)
Treatment of MOPP‐refractory Hodgkin‐s disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine (1983) (23)
Salvage Therapy for Patients With Germ Cell Tumor. (2016) (23)
Have new aggressive chemotherapy regimens improved results in advanced germ cell tumors? (1986) (22)
Combination chemoimmunotherapy of metastatic breast cancer with 5‐fluorouracil, adriamycin, cyclophosphamide, and BCG (1979) (22)
Disseminated seminoma: re-evaluation of treatment protocols. (1981) (22)
Random prospective study cyclophosphamide, doxorubicin, and methotrexate (CAM) combination chemotherapy versus single-agent sequential chemotherapy in non small cell lung cancer. (1982) (22)
Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB. (2006) (22)
Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE). (2017) (22)
Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone‐refractory prostatic cancer: A hoosier oncology group study (1992) (22)
Resection of thoracic and abdominal teratoma in patients after cisplatin-based chemotherapy for germ cell tumor. Late results. (1986) (22)
High-dose chemotherapy for recurrent ovarian germ cell tumors. (2015) (22)
1079 Gemcitabine plus cisplatin in non-small cell lung cancer: A phase II study (1995) (21)
Salvage Chemotherapy With High-Dose Carboplatin and Etoposide With Peripheral Blood Stem Cell Transplant in Patients With Relapsed Pure Seminoma (2011) (21)
Phase II Clinical Trial of Oxaliplatin and Bevacizumab in Refractory Germ Cell Tumors (2014) (21)
Long-term outcome for patients with high volume retroperitoneal teratoma undergoing post-chemotherapy surgery. (2007) (21)
Complicated problems in testicular cancer. (1988) (21)
Flow cytometry derived DNA content of the primary lesions of advanced germ cell tumours. (1987) (21)
Is the blood-brain barrier relevant in metastatic germ cell tumor? (2007) (21)
Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only) (2011) (21)
Radiotherapy in seminoma: more is not better. (1982) (20)
Role of platinum-based chemotherapy for Merkel cell tumor in adjuvant and metastatic settings. (2014) (20)
A Suggested Prognostic Reclassification of Intermediate and Poor‐Risk Nonseminomatous Germ Cell Tumors (2017) (20)
Clinical trials in testicular cancer (1993) (20)
Short- and long-term outcomes after large pulmonary resection for germ cell tumors after bleomycin-combination chemotherapy. (2004) (20)
A phase II trial of olanzapine for the prevention of chemotherapy induced nausea and vomiting (CINV). (2004) (20)
Hepatic Resection for Disseminated Germ Cell Carcinoma (1990) (20)
Are there factors preventing cancer development during embryonic life? (1983) (19)
Coping Skills Practice and Symptom Change: A Secondary Analysis of a Pilot Telephone Symptom Management Intervention for Lung Cancer Patients and Their Family Caregivers. (2018) (19)
Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival. (1996) (19)
Testicular cancer: The usage of central review for pathology diagnosis of orchiectomy specimens. (2017) (19)
The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors. (2015) (19)
Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms (2019) (19)
Testicular tumors : management and treatment (1980) (18)
Outcomes of postchemotherapy retroperitoneal lymph node dissection following high‐dose chemotherapy with stem cell transplantation (2015) (18)
SEMS trial: Result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma. (2021) (18)
Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection: outcome analysis (1994) (18)
Modified neck dissection for metastatic testicular carcinoma. (1985) (18)
Heterogeneity among germ cell tumors of the testis. (1985) (18)
Post chemotherapy RPLND in patients with elevated markers: current concepts and clinical outcome. (2007) (18)
Combination chemotherapy with cis-dichlorodiammineplatinum(II) and adriamycin for testicular cancer refractory to vinblastine plus bleomycin. (1978) (18)
Gallium scans in the evaluation of residual masses after chemotherapy for seminoma. (1995) (18)
Combination chemotherapy with cis-dichlorodiammineplatinum(II) in disseminated testicular cancer. (1979) (17)
Outcomes following surgery for primary mediastinal nonseminomatous germ cell tumors in the cisplatin era. (2020) (17)
Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU. (1977) (17)
A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer (2020) (16)
Phase II Trial of Cimetidine in Metastatic Melanoma: A Hoosier Oncology Group Trial (1991) (16)
Phase II study of vindesine in patients with metastatic breast cancer. (1981) (16)
Chemotherapy of disseminated testicular cancer. (1985) (16)
Chemotherapy of disseminated testicular cancer. (1978) (15)
Pitfalls in management of patients with germ cell tumors and slight elevation of serum α-fetoprotein. (2014) (15)
Support service use and interest in support services among lung cancer patients. (2013) (15)
Combination chemotherapy with doxorubicin and lomustine. Treatment of refractory Hodgkin's disease. (1977) (15)
Binding of medroxyprogesterone acetate in human breast cancer. (1980) (15)
VP-16-213: An active drug in germinal neoplasms (1979) (15)
Phase III study of cisplatin (P) plus etoposide (E) with concurrent chest radiation (XRT) followed by docetaxel (D) vs. observation in patients (pts) with stage III non-small cell lung cancer (NSCLC): An interim toxicity analysis of consolidation therapy. (2006) (15)
Interphase chromosome painting of paraffin-embedded tissue in the differential diagnosis of possible germ cell tumors. (1994) (15)
Is adjuvant chemotherapy following retroperitoneal lymph node dissection for nonseminomatous testis cancer necessary? (1980) (15)
Long-term Survival With Paclitaxel and Gemcitabine for Germ Cell Tumors After Progression Following High-Dose Chemotherapy With Tandem Transplant (2015) (15)
Results of therapy in adult acute lymphocytic leukemia. (1975) (15)
General principles of cancer chemotherapy. (1976) (15)
Sequential combination chemotherapy for advanced, recurrent, squamous carcinoma of the head and neck. (1976) (15)
Ifosfamide in testicular cancer: the Indiana University experience. (1989) (14)
Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients. (2010) (14)
Salvage therapy with high-dose chemotherapy and peripheral blood stem cell transplant in patients with primary mediastinal nonseminomatous germ cell tumors. (2013) (14)
Advanced bladder cancer: therapy with cis-dichlorodiammineplatinum(II), adriamycin, and 5-fluorouracil. (1979) (14)
Lung cancer, thyroid cancer or both: An unusual case presentation. (2011) (14)
Phase II study of etoposide for carcinoma of the prostate. (1986) (14)
Mediastinal yolk sac tumor. The Indiana University experience, 1976 to 1988. (1991) (14)
Ifosfamide: a clinical review. (1989) (14)
Long‐Term Survival of Good‐Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection: A Comparison of BEP × 3 vs. EP × 4 and Treating Institution (2017) (13)
Survival analysis of pure seminoma at post-chemotherapy retroperitoneal lymph node dissection. (2014) (13)
Do all germ cell tumor patients with residual masses in multiple sites require postchemotherapy resections? (1997) (13)
N-acetylcysteine and ifosfamide in the treatment of unresectable pancreatic adenocarcinoma and refractory testicular cancer. (1983) (13)
Signet ring cell carcinoma of the testis: clinicopathologic and molecular evidence for germ cell tumor origin--a case report. (2012) (13)
Chemotherapy of metastatic seminoma (1979) (13)
Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724) (2020) (13)
Combined therapy for small cell undifferentiated carcinoma of the lung. (1978) (12)
Combination chemotherapy of disseminated testicular carcinoma with Cis-diammine-dichloroplatinum, vinblastine, and bleomycin (PVB): an update (1978) (12)
Salvage chemotherapy with high-dose carboplatin plus etoposide and autologous peripheral blood stem cell transplant in male pure choriocarcinoma: a retrospective analysis of 13 cases (2007) (12)
Cisplatin plus VP-16 in small-cell lung cancer. (1986) (12)
Treatment strategies of testicular cancer in the United States. (1987) (12)
Remission induction with daunomycin, vincristine, and prednisone in adult acute lymphocytic leukemia. (1977) (11)
Late relapse of ovarian dysgerminoma: case report and literature review. (1999) (11)
Risk of Bleomycin-Related Pulmonary Toxicities and Operative Morbidity After Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Good-Risk Germ Cell Tumors. (2018) (11)
CISPLATIN CHEMOTHERAPY OF TESTICULAR CANCER (1980) (11)
A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors (2019) (11)
Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. (2019) (11)
Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy (2019) (10)
Treatment of advanced adenocarcinoma of the kidney with ICRF-187: a Southeastern Cancer Study Group Trial. (1986) (10)
A phase II trial of VP-16, ifosfamide, cisplatin, vinblastine, and bleomycin in advanced germ-cell tumors. (1996) (10)
Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer. (1992) (10)
General Motors Cancer Research Prizewinners Laureates Lectures. Charles F. Kettering Prize. Clinical trials in testicular cancer. (1993) (10)
Role of the urologist in metastatic testicular cancer. (2007) (10)
Ifosfamide chemotherapy for pancreatic carcinoma (2004) (10)
Cis-platinum in the treatment of testicular and other cancers. (1982) (10)
Cancer of the testis: a new paradigm. (1986) (10)
American Society of Clinical Oncology 2001 Presidential Initiative: impact of regulatory burdens on quality cancer care. (2002) (10)
Emetic potential of daily oral etoposide (2006) (10)
Ma-2 paraneoplastic encephalitis in the presence of bilateral testicular cancer: diagnostic and therapeutic approach. (2009) (10)
Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management (2019) (9)
Status of chemotherapy for testis cancer. (1987) (9)
Carboplatin (CBDCA) Plus Alpha Interferon In Metastatic Non‐Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Trial (1993) (9)
Neuroimaging of disseminated germ cell neoplasms. (1990) (9)
Primary mediastinal germ cell tumor evolving into an extramedullary acute megakaryoblastic leukemia causing cord compression. (2008) (9)
Vasculogenic Mesenchymal Tumor: A Clinicopathologic and Molecular Study of 55 Cases of a Distinctive Neoplasm Originating From Mediastinal Yolk Sac Tumor and an Occasional Precursor to Angiosarcoma. (2020) (9)
The author replies [9] (2007) (9)
The chemotherapy of testicular cancer. (1982) (9)
Combination chemotherapy with bleomycin (NSC 125066), adriamycin (NSC 123127), CCNU (NSC 79037), vincristine (NSC 67574), and mechlorethamine (NSC 762) (BACON) in squamous cell lung cancer: experience with 50 patients (1975) (9)
Paclitaxel plus gallium nitrate and filgrastim in patients with refractory malignancies: a phase I trial. (1998) (9)
Nabilone (N) anti-emetic crossover study in cancer chemotherapy patients (1978) (9)
Phase II evaluation of mitoxantrone in patients with bronchogenic carcinoma: a Southeastern Cancer Study Group trial. (1984) (9)
Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer (1991) (9)
Paclitaxel (P) plus bevacizumab (B) in patients (pts) with chemosensitive relapsed small cell lung cancer (SCLC): A safety, feasibility and efficacy trial from the Hoosier Oncology Group (2008) (9)
A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma (1992) (9)
Phase II trial of pembrolizumab in patients (pts) with incurable platinum refractory germ cell tumors (GCT). (2017) (9)
Familial occurrence of testicular cancer. (1994) (8)
Why oncologists should support single-payer national health insurance. (2014) (8)
What are the indications for postchemotherapy retroperitoneal lymph node dissection? (2014) (8)
Disseminated testicular cancer: current chemotherapy strategies. (1989) (8)
Phase II evaluation of iproplatin in refractory germ cell tumors: a Southeastern Cancer Study Group trial. (1987) (8)
High‐dose Carboplatin and Mitoxantrone with Autologous Bone Marrow Support in the Treatment of Advanced Breast Cancer (1993) (8)
Clinical stage I testis tumors: the medical oncologist's view. (1982) (8)
Oncologic Outcomes Following Surgical Management of Clinical Stage II Sex Cord Stromal Tumors. (2019) (8)
Survival outcomes of patients with metastatic germ cell tumor (mGCT) treated from 1998 to 2012: The Indiana University (IU) experience. (2016) (8)
Clinical trials with ifosfamide: the Indiana University experience. (1992) (8)
Treatment of metastatic germ-cell tumors in men with adriamycin, vincristine, and bleomycin. (1977) (7)
The predictive value of serum tumor markers for pathologic findings after chemotherapy for primary mediastinal nonseminomatous germ cell tumors. (2008) (7)
A retrospective analysis of patients with intermediate-risk germ cell tumor (IRGCT) treated at Indiana University from 2000 to 2010. (2012) (7)
Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors (2020) (7)
Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors (2020) (7)
Outcome following resection for patients with primary mediastinal nonseminomatous germ cell tumors and rising serum tumor markers post-chemotherapy. (2008) (7)
E21. Carboplatin versus cisplatin in lung cancer (2005) (7)
Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer. (2002) (7)
Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer? (2017) (7)
High‐dose chemotherapy plus peripheral blood stem cell transplantation for patients with relapsed germ cell tumors and active brain metastases (2019) (7)
Phase II study of etoposide for carcinoma of the bladder: the Southeastern Cancer Study Group experience. (1986) (7)
Salvage chemotherapy with high dose carboplatin + etoposide (HDCE) and peripheral blood stem cell transplant (PBSCT) in patients with germ cell tumors (GCT). (2006) (7)
The chemotherapy of testicular cancer (1982) (7)
Vindesine and mitomycin C in metastatic breast cancer. A Southeastern Cancer Study Group Trial. (1989) (7)
Phase II study of AMSA in refractory testicular cancer. (1983) (7)
Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments (2022) (7)
Surgical therapy for testicular cancer metastatic to the liver. (2007) (7)
Can prenatal irradiation protect the embryo from tumor development? (1991) (7)
Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study (2016) (7)
Long-Term Toxicity of Radiation Therapy (2003) (7)
Toxicity comparisons between two chemotherapy regimens as adjuvant or salvage treatment in nonseminomatous testicular cancer (1988) (7)
Long-Term Oncologic Outcomes after Primary Retroperitoneal Lymph Node Dissection: Minimizing the Need for Adjuvant Chemotherapy. (2019) (7)
B5-01: Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023 (2007) (7)
VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer (2004) (6)
Dramatic Response of Teratoma‐Associated Non‐Germ‐Cell Cancer With All‐Trans Retinoic Acid in a Patient with Nonseminomatous Germ Cell Tumor (2001) (6)
O-5 Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed versus docetaxel in non-small-cell lung cancer (NSCLC) (2003) (6)
Results of retroperitoneal lymph node dissection after chemotherapy in patients with pure seminoma in the orchidectomy specimen but elevated serum α‐fetoprotein (2009) (6)
Combination chemotherapy, radiotherapy, and immunotherapy in small cell undifferentiated lung cancer (1977) (6)
Value of radiation therapy to the thorax in limited small cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation (1984) (6)
Surgical management of late relapse on surveillance in patients presenting with clinical stage I testicular cancer. (2014) (6)
Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC. A Hoosier Oncology Group (HOG) phase II study. (2002) (6)
Adverse health outcomes in relationship to hypogonadism (HG) after platinum-based chemotherapy: A multicenter study of North American testicular cancer survivors (TCS). (2017) (6)
A phase II trial of olanzapine and palonosetron for the prevention of chemotherapy induced nausea and vomiting (CINV). (2006) (6)
Title of paper: A phase III study of thoracic radiation with or without concurrent cisplatin chemotherapy in locoregional unresectable non-small cell carcinoma of the lung. a hoosier oncology group protocol (1991) (6)
Phase II study of oxaliplatin (O) and bevacizumab (B) chemotherapy in refractory germ cell tumors (GCT). (2010) (6)
Very late relapse of germ cell tumor as a teratoma: a case report and review of the literature (2014) (6)
A Phase II trial of high dose epirubicin in patients with advanced breast carcinoma (2000) (5)
Phase II clinical trial of oxaliplatin and bevacizumab in refractory metastatic germ cell tumors (GCT). (2011) (5)
Pharmacogenomics of cisplatin‐induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy (2021) (5)
Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. (2008) (5)
Brentuximab Vedotin in Patients With CD30+ Mesothelioma (2014) (5)
Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide for patients with relapsed primary mediastinal nonseminomatous germ cell tumors: benefit from chemotherapy, surgery, or both? (2010) (5)
Testicular Cancer: The Indiana University Experience (1980) (5)
Prognostic Value of Teratoma in Primary Tumor and Postchemotherapy Retroperitoneal Lymph Node Dissection Specimens in Patients With Metastatic Germ Cell Tumor. (2020) (5)
Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy. (2006) (5)
Phase II Study of Ifosfamide Plus Daily Oral Etoposide in Previously Treated Ovarian Cancer: A Hoosier Oncology Group (HOG) Study (2004) (5)
Preliminary results of a randomized trial to evaluate the role of radiotherapy in the combined modality therapy of limited stage small cell lung cancer (1981) (5)
Advanced seminoma and nonseminoma: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. (2011) (5)
Comparison of cisplatin + bleomycin + either vinblastine or VP-16 in disseminated testicular cancer: a preliminary report. (1984) (5)
Tumor Marker Rise during Second Course of High-Dose Chemotherapy in Cancer: Outcome Analysis (2013) (5)
Chronic health conditions (CHCs) following cisplatin-based chemotherapy (CHEM): A multi-institutional study of 680 testicular cancer survivors (TCS). (2015) (5)
Combination chemotherapy with adriamycin (NSC-123127) and 1-(2-chloroethyl)-3-cyclohexyl 1-nitrosourea (CCNU; NSC-79037). (1973) (5)
Phase II study of sulofenur (LY 186641). A novel antineoplastic agent in advanced non-small cell lung cancer. (1993) (5)
Salvage therapy in patients with germ cell tumors. (2015) (5)
What to do when you discover testicular cancer. Helping patients overcome fear and choose treatment. (1999) (5)
Cisplatin Dose-intensity in Testicular Cancer Treatment: Analysis of a Randomized Clinical Trial (1991) (5)
Salvage chemotherapy for patients with germ cell tumors: is there a best regimen? (2012) (4)
Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. 1997. (2002) (4)
Curable neoplasms and the ethics of clinical trials. (1993) (4)
Palonosetron (PALO) + dexamethasone (DEX) for prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) in patients receiving multiple-day cisplatin CT for germ cell cancer. (2006) (4)
Recurrent testis cancer: seeding from retroperitoneal nodes after complete remissions by chemotherapy. (1983) (4)
Antiemetics: A Round Table Discussion (1983) (4)
Metachronous intracranial germinoma in a patient with a previous primary mediastinal seminoma. (2006) (4)
Approaches to drug therapy in older cancer patients. (1992) (4)
Combination chemotherapy of ovarian carcinoma with Cis-diamminedichloroplatinum (CDDP), adriamycin (ADR) and cytoxan (CTX) (1978) (4)
Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer (NSCLC): A phase II study from the Hoosier Oncology Group. (2006) (4)
Testicular Cancer: Biology to Bedside (2021) (4)
Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study (2021) (4)
Dose intensity in germ cell cancer: continued lessons from a model neoplasm. (1993) (4)
Response, 'second look' status and survival in stage III-IV epithelial ovarian cancer treated with cis-dichlorodiammine platinum II (cis-platinum), adriamycin (ADR), and cytoxan (CTX) (1980) (4)
Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors (2021) (4)
Survival outcomes and toxicity in patients 40 years old or older with relapsed metastatic germ cell tumors treated with high‐dose chemotherapy and peripheral blood stem cell transplantation (2021) (4)
Will we ever have personalized medicine for non-small cell lung cancer? (2006) (4)
Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors (1992) (4)
Love in the Time of Cancer. (2017) (3)
Adriamycin (ADR) plus cis-diamminedichloroplatinum (CPDD) in refractory disseminated testicular cancer (1978) (3)
A phase II study assessing the safety and efficacy of ASP1650 in male patients with incurable platinum refractory germ cell tumors. (2020) (3)
Interim results of phase II trial of the cyclin-dependent kinase 4/6 inhibitor PD-0332991 in refractory retinoblastoma protein positive germ cell tumors. (2012) (3)
Tumor marker rise during second course high-dose chemotherapy in recurrent testicular cancer: Outcome analysis. (2011) (3)
Salvage therapy for relapsed testicular cancer (2017) (3)
Results from a randomized study of carboplatin and etoposide (CE) with or without palifosfamide (Pa) in extensive stage small cell lung cancer (ES-SCLC): The MATISSE study. (2015) (3)
Phase II trial of high-dose cisplatin plus etoposide plus vinblastine in non-small-cell lung cancer. A Hoosier Oncology Group study. (1991) (3)
A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors (2022) (3)
A case of relapsed testicular cancer initially isolated to the spleen. (2009) (3)
Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplants. (2011) (3)
Metabolic syndrome (MetS) after platinum-based chemotherapy (CHEM): A multicenter study of North American testicular cancer survivors (TCS). (2017) (3)
Cis-diamminedichloroplatinum (P) + vinblastine (V) + bleomycin (B) + adriamycin (ADR) in disseminated testicular cancer (1979) (3)
Non-small cell lung cancer: Improved chemotherapy (1997) (3)
Perioperative morbidity and mortality with bleomycin in primary mediastinal non seminomatous germ cell tumor (PMNSGCT). (2015) (3)
A phase II multicenter evaluation of ARQ 197 monotherapy in patients with relapsed or refractory germ cell tumors (GCTs). (2011) (3)
Chemotherapy-Related Chronic Myelogenous Leukemia: A Case Series of Patients With Germ Cell Tumor. (2016) (3)
Long-Term Toxicity of Chemotherapy (2003) (3)
P-508 Elderly patients benefit from second-line cytotoxic chemotherapy for advanced non-amall cell lung cancer (2005) (3)
Management of residual disease after chemotherapy in germ cell tumors. (2020) (3)
Maintenance Oral Etoposide After High-Dose Chemotherapy (HDCT) for Patients With Relapsed Metastatic Germ-Cell Tumors (mGCT). (2020) (3)
Seminar article Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer (2005) (3)
A retrospective analysis of patients with metastatic germ cell tumor (GCT) treated at Indiana University (IU) from 2000 to 2012. (2015) (3)
Chemotherapy of advanced testicular cancer. (1985) (3)
Effect of the C3435T genetic polymorphism in MDR1 on etoposide pharmacokinetics (2008) (3)
Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130 (2017) (3)
Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy (2005) (3)
Comprehensive characterization of cisplatin-related hearing loss in U.S. and Canadian Testicular Cancer Survivors (TCS). (2015) (3)
Phase II study of sulofenur (LY 186641) (1993) (3)
Small Cell Lung Cancer: Treatment for Extensive Stage Disease (2004) (3)
Combined modality therapy in esophageal cancer. (1990) (3)
Postchemotherapy retroperitoneal lymph node dissection in patients presenting with very high HCG levels. (2020) (3)
Three-dimensional lymph node volume and craniocaudal lymph node length as an independent risk factor for recurrence or presence of micrometastatis in clinical stage I non-seminomatous germ cell tumors: A retrospective study. (2015) (2)
Phase II study of fosaprepitant +5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: A Hoosier Cancer Research Network Study. (2015) (2)
Combination chemotherapy with vinblastine (V), adriamycin (A), bleomycin (B), CCNU (C), and DTIC (D) for MOPP-refractory Hodgkin's disease (HD) (1982) (2)
Current chemotherapy strategy in patients with germ cell tumors. (1993) (2)
High-dose chemotherapy (HDCT) and autologous peripheral-blood stem cell transplant (PBSCT) for relapsed metastatic germ-cell tumors (mGCT): The Indiana University (IU) experience. (2016) (2)
Apparent surgical cure for metastatic small cell lung cancer. (2008) (2)
Controversies in the management of clinical stage 1 testis cancer. (2020) (2)
Phase III, double-blind, placebo-controlled, crossover study evaluating a 5HT3 antagonist plus dexamethasone with or without aprepitant in patients with germ cell tumor receiving 5-day cisplatin combination chemotherapy: A Hoosier Oncology Group (HOG) study. (2011) (2)
Cardiovascular disease (CVD) risk factors among cisplatin-treated testicular cancer survivors (TCS): A multicenter clinical study of U.S. and Canadian patients. (2015) (2)
Genome-wide association study of cisplatin-induced peripheral neuropathy (CIPN) in testicular cancer survivors. (2016) (2)
Retrospective, correlative study of BRAF mutation V600E in testicular cancer patients. (2013) (2)
266 A phase II study of VP-16 plus ifosfamide plus cisplatin (VIP) plus concurrent radiation therapy (XRT) for previously untreated limited small cell lung cancer (SCLC): A Hoosier Oncology Group (HOG) trial (1997) (2)
Correlation of clonogenic growth with histologic diagnosis after resection of residual tissue following chemotherapy for nonseminomatous testis cancer. (1989) (2)
Radiotherapy in Seminoma: More is Not Better (1983) (2)
Cyclophosphamide and ifosfamide: role of uroprotective agents. (1990) (2)
High-dose chemotherapy (HDCT) plus peripheral-blood stem-cell transplant (PBSCT) for patients (pts) with relapsed germ-cell tumors (GCT) and active brain metastases (mets). (2017) (2)
Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer (1993) (2)
The value of platinum compounds in non-small-cell lung cancer. (2002) (2)
Etoposide and Split‐Dose Cisplatin in Bronchogenic Carcinoma (1988) (2)
CODE (cisplatin, vincristine, doxorubicin, etoposide) plus granulocyte colony-stimulating factor in advanced non-small-cell lung cancer: a Hoosier Oncology Group phase II trial. (1998) (2)
A Canadian approach to the regionalization of testis cancer: A review. (2019) (2)
Vindesine: an Effective Phase II Agent in the Treatment of Non-Small Cell Lung Cancer (1981) (2)
Biology of metastases and its clinical implications: testicular germ-cell tumors (2004) (2)
Clinical dilemmas in local and regional testis cancer. (2020) (2)
Orchiectomy alone in clinical stage A disease (1984) (2)
The effects of hypogonadism on quality of life in survivors of germ cell tumors treated with surgery alone versus surgery plus platinum-based chemotherapy (2019) (2)
Postoperative chemotherapy for n2 non-small-cell lung cancer: conclusions are not black and white, but gray. (2006) (2)
591: Do Postchemotherapy Patients who Present with an Elevated Serum AFP and Pure Seminoma in the Orchiectomy Specimen Have a Higher Probability of Finding Necrosis only in the Retroperitoneal Lymph Node Dissection (RPLND) Specimen? (2006) (2)
Late relapse of germ cell tumors: Detection and treatment outcomes. (2021) (2)
Extensive small cell lung cancer: trials of Indiana University and the Hoosier Oncology Group (1993) (2)
A retrospective analysis of patients with poor-risk germ cell tumor (PRGCT) treated at Indiana University from 1990 to 2011. (2014) (2)
Is the blood-brain barrier relevant in metastatic germ cell tumors? (2007) (2)
A phase III hoosier oncology group study of thoracic radiotherapy (TRT) plus cisplatin (P) and vinblastin (V) with or without hydroxgurea (HX) for locally unresectable non small cell lung cancer (NSCLC) (1998) (2)
Editorial Treatment of advanced disseminated germ cell tumors (1991) (2)
A retrospective analysis to identify variables predictive of achieving a pCR after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer (2004) (2)
Psychotropic and stimulant medication (PSM) use among testicular cancer survivors (TCS): A multi-institutional clinical study of 680 patients given cisplatin-based chemotherapy (CHEM) (NCI 1R01 CA157823-02). (2016) (2)
Total-body irradiation with 25-MV photons in advanced non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Preliminary results and complications. (1978) (2)
A phase I study of guadecitabine (SGI-110) plus cisplatin in patients with platinum refractory germ cell tumors. (2020) (2)
Urologic neoplasia series. Cytoreductive surgery for metastatic testis cancer: considerations of timing and extent. (1979) (2)
Percentage of Teratoma in Orchiectomy and Risk of Retroperitoneal Teratoma at the Time of Postchemotherapy Retroperitoneal Lymph Node Dissection in Germ Cell Tumors (2021) (2)
Malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): Outcome analysis with PNET based chemotherapy. (2009) (1)
Associated With Primary Mediastinal Nonsemino-matous Germ Cell Tumors (1999) (1)
Randomized phase 2 trial of maintenance oral etoposide or observation following high-dose chemotherapy for relapsed metastatic germ cell tumor. (2022) (1)
A phase II study of the safety and efficacy of the MDR inhibitor VX-710 combined with doxorubicin and vincristine in small cell lung cancer. (2006) (1)
SELDI may facilitate the management of germ cell tumor (2005) (1)
Cisplatin, vinblastine, and bleomycin as second-trial therapy in ovarian carcinoma. A pilot study of the Gynecologic Oncology Group. (1985) (1)
Disseminated testicular cancer - Refining the cure (1989) (1)
Prostate carcinoma presenting as multiple pulmonary nodules in an asymptomatic patient with a history of testicular nonseminomatous germ cell tumor. (2003) (1)
Metastatic malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): Results with PNET-based chemotherapy. (2012) (1)
Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors (2010) (1)
Salvage therapy for relapsed testicular cancer (2017) (1)
Cisplatin, adriamycin, and cyclophosphamide (PAC) combination chemotherapy in stage III–IV epithelial ovarian cancer: 7-Year follow-up (1986) (1)
Cardiovascular disease (CVD) risk factors and health behaviors following cisplatin-based chemotherapy (CHEM): A multi-institutional study of testicular cancer survivors (TCS). (2016) (1)
Outcome Analysis for Patients with Persistent Non-Seminomatous Germ Cell Tumour in Post-Chemotherapy Retroperitoneal Lymph Node Dissections (1994) (1)
A phase II study of cisplatin, 5 fluorouracil (5-FU), radiation (RT) and celecoxib in patients with resectable esophageal cancer (EC): Updated results from the Hoosier Oncology Group (HOG) study. (2004) (1)
Prognostic significance of rate of tumor marker (TM) decline during high-dose chemotherapy (HDCT) for relapsed germ cell tumors (rGCT). (2020) (1)
Primary Teratoma of the Lesser Sac: Lesser Sac Teratoma (2012) (1)
Diagnostic and therapeutic quandaries in a patient with a germ cell tumor. (2001) (1)
Chemotherapeutic approaches to the treatment of testicular cancer. (1988) (1)
Phase II evaluation of amsacrine in small cell lung cancer: a Southeastern Cancer Study Group trial. (1985) (1)
High-dose chemotherapy (HDCT) for recurrent ovarian germ cell tumors (OGCT): Indiana University (IU) experience. (2014) (1)
Barriers to sperm banking in testicular cancer survivors. (2015) (1)
Combination chemotherapy of refractory Hodgkin's disease (HD) with adriamycin (ADR) and CCNU (1977) (1)
Prolonged Survival With Reinstitution of High-Dose Chemotherapy With Peripheral Blood Stem-Cell Transplantation in a Patient With Refractory Testis Cancer. (2019) (1)
2016MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients (2016) (1)
Immunological markers of outcome of non-small cell lung cancer (2005) (1)
Cardiovascular disease (CVD) risk factors and health behaviors after cisplatin-based chemotherapy (CHEM): A multi-institutional study of testicular cancer survivors (TCS) in the Platinum study. (2016) (1)
Hearing loss after cisplatin-based chemotherapy: Patient-reported outcomes versus audiometric assessments. (2021) (1)
Can patients (pts.) with refractory germ cell tumors (GCT) be cured after progression following high dose chemotherapy (HDCT) with tandem transplant? Results with paclitaxel + gemcitabine. (2006) (1)
Comprehensive association analysis of speech recognition thresholds after cisplatin‐based chemotherapy in survivors of adult‐onset cancer (2022) (1)
Genome-wide association study (GWAS) of cisplatin-related hearing loss in testicular cancer survivors (TCS) to reveal associated variant in Wolfram syndrome 1 (WFS1) gene. (2016) (1)
Adjuvant Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors: Is This the Preferred Option? (2020) (1)
MTE 23.02 Mediastinal Germ Cell Tumor (2017) (1)
A pilot study to assess the accuracy of “intuition” in analyzing post chemotherapy (chemo) residual retroperitoneal (RP) masses in patients (pts) with non seminomatous germ cell tumor (NSCGCT). (2018) (1)
“Testicular Cancer: A Model for a Curable Cancer” (2014) (1)
Gene expression profiling in germ cell tumors. (2004) (1)
Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy (2023) (1)
Clinical course of patients with cisplatin (CDDP)-associated neuropathy compared to other neurotoxic chemotherapy. (2019) (1)
Reply to the letter to the editor 'A centralised multidisciplinary clinic approach for germ cell tumours' by Crawford. (2018) (1)
Prediction model for brain metastasis (BM) in patients with metastatic germ-cell tumors (mGCT) accounting for size of pulmonary metastases. (2021) (1)
VP-16 plus ifosfamide plus cisplatin (VIP) in refractory germ cell tumors (1986) (1)
Introduction: Current developments and future directions with ifosfamide: An update (1992) (1)
Larry Einhorn--President of ASCO, 2000-2001. American Society of Clinical Oncology (interview by Sue Silver). (2001) (1)
Complete remission in refractory Burkitt's lymphoma. (1984) (1)
High Resolution Genomic Profiling of Metastatic Testicular Teratomas (2013) (1)
NONSEMINOMA GERM CELL TESTIS TUMOR MANAGED BY RETROPERITONEAL LYMPH NODE DISSECTION (2000) (1)
Restriction of cloning potential in agarose of early chick embryonic cells as development progresses. (1986) (1)
Phase II study of mitomycin in small cell lung carcinoma. (1986) (1)
Results of chemotherapy of disseminated malignant melanoma (1974) (1)
Emetic potential of daily oral etoposide. (2006) (1)
A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. A Hoosier Oncology Group study. (1992) (1)
Aggressive surgical management of germ cell tumors with somatic-type malignancy: Pathologic features, prognostic factors, and survival outcomes. (2013) (1)
Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy (2023) (1)
Current Treatment of Testicular Cancer (1990) (1)
Current perspectives on the use of etoposide. Introduction. (1992) (1)
Long-term health outcomes of germ cell tumor survivors. (2016) (1)
Comprehensive genomic profiling (CGP) in patients with relapsed/refractory germ cell tumors (GCT). (2020) (1)
Surveillance after Complete Response to First-Line Chemotherapy in Patients with Metastatic Nonseminomatous Germ Cell Tumor (2022) (1)
Management of Metastatic Pure Teratoma in Chemotherapy Naive Patients With Testicular Primaries (2020) (1)
Phase II study of fosaprepitant plus 5HT3 receptor antagonists plus dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: Hoosier Oncology Group QL12-153. (2014) (1)
Clinical, sociodemographic, and behavioral factors associated with cumulative burden of morbidity (CBM) among testicular cancer survivors (TCS) in the Platinum study. (2017) (1)
CASE REPORT Late Relapse of Ovarian Dysgerminoma: Case Report and Literature Review (1999) (1)
Curing cancer and successful supportive care: promises fulfilled and unrealistic expectations (2003) (1)
Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. (2023) (1)
Genomic analysis for potential targetable mutations in relapsed and refractory germ cell tumors. (2020) (1)
Variation in protein-coding sequence and the genetic basis of cisplatin-induced toxicities among testicular cancer survivors (TCS) in the Platinum Study. (2016) (1)
A phase II single arm multi-center trial evaluating the efficacy of pembrolizumab in the treatment of patients (pts) with incurable platinum refractory germ cell tumors (GCT). (2016) (1)
Autotransplants for germ cell tumor: How best to do it (2017) (1)
Long-term follow-up of chemotherapy-induced remissions in patients with disseminated nonseminomatous germ cell tumors. (2009) (0)
Society News 12/11 (2004) (0)
Treatment of Patients with “Poor-Risk” Disseminated Disease (2003) (0)
Results a nd O utcome o f R etroperitoneal L ymph N ode Dissection f or C linical S tage I E mbryonal Carcinoma-Predom inant T estis C ancer (2000) (0)
Multimodality of Germ Cell Tumors of the Mediastinum (2009) (0)
Causes and patterns of mortality in patients with lethal germ cell tumor (GCT). (2020) (0)
Salvage high-dose chemotherapy (HDCT) for relapsed primary mediastinal nonseminomatous germ-cell tumors (PMNSGCT). (2022) (0)
Remaining Issues in Germ Cell Tumors (1997) (0)
Coarctation of the Aorta (2002) (0)
Cisplatin-induced tinnitus (CIS-TINN) and patient-reported outcomes in adult-onset cancer survivors. (2022) (0)
Adjuvant therapy following surgery in breast cancer. (1977) (0)
A phase I study of amrubicin (AMR) and cyclophosphamide in patients with advanced solid organ malignancies: A trial from the Hoosier Oncology Group. (2011) (0)
O-156 Randomized, phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated, extensive-stage, small-cell lung cancer (SCLC) (2005) (0)
Romantic and Sexual Relationships in Testicular Cancer Survivors Interview (2014) (0)
Prolonged Survival With Reinstitution of High-Dose Chemotherapy With Peripheral Blood Stem-Cell Transplantation in a Patient With Refractory Testis Cancer. (2020) (0)
Hypogonadism and effects on quality of life in previously treated germ cell tumor survivors: A single-centre, non-randomized, prospective observational study. (2018) (0)
N.S.E. in testicular germ cell tumors (1993) (0)
711 MANAGEMENT OF MALIGNANT TRANSFORMATION DIAGNOSED EARLY IN THE TREATMENT OF GERM CELL TUMORS (2013) (0)
Re: Review of Delayed Orchiectomy in Patients with Disseminated Testis Tumors by, B. W. Snow, R. G. Rowland, J. P. Donohue, L. H. Einhorn and S. D. Williams, J. Urol., 129: 522–523, 1983 (1984) (0)
A retrospective analysis to identify variables predictive of achieving a pCR after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer. (2004) (0)
Decreased T cell infiltration and lymphocyte/dendritic cell/monocyte gene expression as well as increased Cyp3A5 mRNA predicts early recurrence of non-small cell lung cancer (NSCLC) following surgical resection. (2004) (0)
A prognostic model for response and outcome in patients with extragonadal germ cell tumors — an international multivariate analysis (2001) (0)
American S ociety o f C linical O ncology 2 001 P residential Initiative: I mpact o f R egulatory B urdens o n Q uality Cancer C are (2002) (0)
Measurement of patients’ acceptable symptom levels and priorities for symptom improvement in advanced lung cancer (2021) (0)
Neuroimaging of Disseminated Germ Cell Neoplasms 319 (2013) (0)
Late Relapse of Germ Cell Tumors After Prior Chemotherapy or Surgery-only. (2023) (0)
Suggested reclassification strategy applied to intermediate and poor risk nonseminomatous germ cell tumors (NSGCT): A two-institution combined analysis. (2016) (0)
Cancer chemotherapy. (1973) (0)
Binding of medroxy~rogesterone acetate in ~~rnan breast cancer (1980) (0)
Abstract 5169: Tissue analysis of NAD(P)H: quinone oxidoreductase (NQO1) and catalase expression in patients with germ cell tumors (GCT) (2020) (0)
Abstract B53: Multicenter phase Ib study of the safety and efficacy of palifosfamide plus carboplatin/etoposide (PaCE) in patients with small cell lung cancer or other selected cancers. (2011) (0)
Risk stratification of clinical stage I (CSI) non-seminomatous germ cell testicular tumors (NSGCT): A retrospective analysis of experience at Indiana University (IU). (2016) (0)
Systemic chemotherapy for testicular cancer (2012) (0)
Fluoxetine V ersus P lacebo i n A dvanced C ancer O utpatients: A Double-Blinded T rial o f t he H oosier O ncology G roup (2003) (0)
Unrecognized Germ Cell Tumor Syndrome (2003) (0)
PL05.07: A Wise Man’s Conclusion (2017) (0)
Therapy for Disseminated Disease (2003) (0)
Neuroimaging of disseminated germ cell neoplasms. (1990) (0)
Perspective on the development of new agents in thoracic cancers. (2005) (0)
Management of pure metastatic teratoma in chemotherapy naïve testis cancer patients. (2017) (0)
Contents, Vol. 32, 1975 (1970) (0)
High-Dose Chemotherapy as Initial Salvage Therapy (2003) (0)
Genome-wide association study (GWAS) of chemotherapy-induced Raynaud's phenomenon (RP) to reveal shared pathways with cardiovascular disease (CVD). (2017) (0)
Integration of a polygenic risk score of kidney function with cumulative cisplatin dose and time variables for the prediction of serum platinum levels. (2021) (0)
Relationships, Sexuality, and Fertility in Adolescent and Young Adult Testicular Cancer Survivors (2010) (0)
Salvage therapy with high-dose chemotherapy (HDCT) and peripheral blood stem cell transplant (PBSCT) in patients with primary mediastinal nonseminomatous germ cell tumors (PMNSGCT). (2011) (0)
Abstract 2999: Low-dose demethylation therapy for the treatment of cisplatin-resistant testicular cancer (2018) (0)
Role of the Human Apurinic Endonuclease Ape1/ref-1 in Germ Cell Tumours (2002) (0)
Phase I II M ulticenter R andomized T rial o f t he D artmouth Regimen V ersus D acarbazine i n P atients With M etastatic M elanoma (1999) (0)
Pharmacokinetic (PK) modeling of serum platinum to reveal extent of long-term exposure and associated comorbidities after cisplatin treatment. (2018) (0)
Ifosfamide in small cell lung cancer. (1989) (0)
Prevalence of hypogonadism in patients with previously treated germ cell tumors. (2015) (0)
Chemotherapy of advanced testicular cancer. (1984) (0)
Treatment of advanced disseminated germ cell tumors. (1991) (0)
Chemotherapy for Advanced Thymoma (2020) (0)
Chemotherapy of disseminated testicular cancer. (1979) (0)
Acceptance and Commitment Therapy for Symptom Interference inAdvanced Lung Cancer and Caregiver Distress: A Pilot RandomizedTrial (2019) (0)
Pearls and perils in the management of germ cell tumors (2021) (0)
Expression of circulating miR375 and miR371 to differentiate teratoma and viable germ cell tumor in patients with post-chemotherapy residual disease. (2020) (0)
Differences in clinical characteristics and outcomes between white (W) and non-white (NW) patients with metastatic germ cell tumor (mGCT) treated at Indiana University (IU). (2020) (0)
TREATMENT OF TESTICULAR TUMOURS (1983) (0)
Update in testicular cancer (1999) (0)
Advanced Extragonadal Germ-Cell Tumors (2020) (0)
Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? (2022) (0)
Random prospective study of cyclophosphamide (C), adriamycin (A), and methotrexate (M) combination chemotherapy (CAM) vs. single agent sequential chemotherapty (C,A,& M) in non-small cell lung cancer (NSCLC) (1982) (0)
Impact of cisplatin-related adverse health outcomes (AHOs) on employment outcomes and self-reported health (SRH) among testicular cancer survivors (TCS). (2019) (0)
Cancer chemotherapy. (1977) (0)
Epidemiology of Mediastinal Germ Cell Neoplasms (2018) (0)
Systemic Chemotherapy in the Management of Bladder Cancer (1983) (0)
Patients with advanced-stage germ cell tumors have a high risk of thromboembolic events. (2013) (0)
New directions in treatment of poor risk and recurrent germ cell cancer : review of American clinical trails using high-dose chemotherapy (1992) (0)
Surgical "salvage" therapy for intrathoracic chemorefractory metastases from non-seminomatous germ cell cancer of testicular origin: An institutional retrospective review. (2004) (0)
Adjuvant chemotherapy with CAV/IE for malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): An institutional analysis from Indiana University. (2021) (0)
Urological Survey: Abstracts: Diagnostic Urology and Testis CancerPostchemotherapy Retroperitoneal Lymph Node Dissection is Effective Therapy in Selected Patients With Elevated Tumor Markers After Primary Chemotherapy Alone (1998) (0)
Contributors (2012) (0)
Causes and patterns of mortality in patients diagnosed with germ cell tumour (GCT) (2019) (0)
Retroperitoneal cancer viability after postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in good risk germ cell tumors (GCTs). (2018) (0)
O-280 Phase III study comparing irinotecan (IRI) and cisplatin (CDDP) to cisplatin and etoposide (VP) for prevlously untreated extensive small cell lung cancer: Interim safety analysis (2003) (0)
Treatment of Mediastinal Germ Cell Tumors by Surgery (2018) (0)
Navelbine: How I Use It (1997) (0)
Outcomes of patients with germ cell tumors diagnosed with stage I disease who subsequently received high dose chemotherapy (HDCT) with peripheral stem cell transplant (PBSCT) following failure of initial therapy for metastatic disease: The Indiana University experience. (2021) (0)
Model to predict brain metastasis (BM) in patients with metastatic germ-cell tumors (mGCT). (2020) (0)
Estimation of 10-year (y) cardiovascular disease (CVD) risk after cisplatin-based chemotherapy (CBCT): A multi-institutional study of 459 germ cell tumor (GCT) survivors in the Platinum study. (2016) (0)
Adverse health outcomes (AHO) after modern cisplatin-based chemotherapy (CHEM) compared to surgery-only: A study of 503 testicular cancer survivors (TCS). (2018) (0)
Safety and tolerability of guadecitabine (SGI-110) plus cisplatin in patients (pts) with platinum-refractory germ cell tumors (GCT): Preliminary results from an open label phase 1b study. (2018) (0)
Adverse health outcomes (AHO) in testis cancer survivors (TCS) following high-dose chemotherapy (HDCT) and autologous stem cell transplant. (2022) (0)
Antidepressant Relieves Depression but Not Fatigue in Cancer Patients CANCER INFORMATION RESOURCES (0)
Long-term Survival of Good Risk Germ Cell Tumor Patients following Post-chemotherapy Retroperitoneal Lymph Node Dissection: A comparison of BEPx3 vs. EPx4 and treating institution (2017) (0)
Treatment of Good-Risk Disseminated Germ Cell Tumors (2003) (0)
A phase II study of venlafaxine for the treatment of hot flashes in men undergoing androgen deprivation for prostate cancer. (2004) (0)
Utilization of sperm banking in men undergoing chemotherapy for testis cancer. (2014) (0)
Final results of a phase I study of amrubicin and cyclophosphamide in patients with advanced solid organ malignancies: HOG LUN 07-130. (2014) (0)
Vindesine, a Phase II Study in Patients with Refractory Metastatic Breast Cancer1 (1981) (0)
Oncologic outcomes of primary retroperitoneal lymph node dissection (RPLND) for stage II seminoma: Indiana University experience. (2022) (0)
Management of Residual Disease After Therapy for Mediastinal Germ Cell Tumor and Normal Serum Markers (2011) (0)
CUAJ – Review Nason et al Regionalization of testis cancer (2020) (0)
Unusual case of long-term survival of the patient with chemorefractory merkel cell carcinoma (2007) (0)
Commentary on Survival after resection for metastatic testicular nonseminomatous germ cell cancer to the lung or mediastinum. (2012) (0)
Prognostic value of serum tumor marker (STM) rate of decline during high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT) for relapsed germ-cell tumors (rGCT). (2019) (0)
PD34-07 DOES TERATOMA METASTASIZE? PRESENCE OF TERATOMA IN THE PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION SETTING (2016) (0)
PD19-05 DOES PERCENTAGE OF SEMINOMA AT ORCHIECTOMY IMPACT PATIENT MORBIDITY AND PATHOLOGIC OUTCOMES AT POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION FOR MIXED GERM CELL TUMOR? (2020) (0)
A phase I study of amrubicin (AMR) and cyclophosphamide in patients with advanced solid organ malignancies: Correlative analysis of a trial from the Hoosier Oncology Group. (2011) (0)
Legends in urology. (2015) (0)
MP33-18 SURGICAL AND ONCOLOGIC OUTCOMES OF SURGERY IN EARLY METASTATIC SEMINOMA: MULTI-INSTITUTIONAL RETROSPECTIVE STUDY (2023) (0)
Management of residual nonretroperitoneal disease in nonseminomatous germ-cell tumors (NSGCT). (2022) (0)
Correction to: Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724) (2021) (0)
Neovascularization in clinical stage I testicular germ cell tumor as a predictor of metastatic disease (2007) (0)
Cumulative burden of morbidity (CBM) among testicular cancer survivors (TCS) in the Platinum study. (2016) (0)
Malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): Outcome analysis with retroperitoneal lymph node dissection and PNET specific chemotherapy. (2009) (0)
Abstract 1386: Safety and tolerability of guadecitabine (SGI-110) plus cisplatin in patients with platinum refractory germ cell tumors (GCT): A phase 1 study (2018) (0)
Surgical Management of Cervical Non‐seminomatous Germ Cell Tumor Metastases (2021) (0)
Current concepts in the evaluation and treatment of Hodgkin's disease. (1978) (0)
Risk Factors for Relapse in Teratoma Resected Postchemotherapy for Metastatic Testis Cancer (1987) (0)
PD56-02 IS THE PERCENTAGE OF TERATOMA IN THE ORCHIECTOMY SPECIMEN PREDICTIVE OF TERATOMA IN THE RETROPERITONEUM AT THE TIME OF POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION IN MEN WITH NON-SEMINOMATOUS GERM CELL TUMORS? (2019) (0)
Abstract 3904: Pharmacokinetic modeling of serum platinum reveals extent of long-term exposure and associated comorbidities after cisplatin treatment (2019) (0)
Update o n L ate R elapse o f G erm C ell T umor: A C linical a nd Molecular A nalysis (2003) (0)
596 Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation (TMT): An international collaboration (2015) (0)
Impact of cisplatin-related hearing loss (HL) and tinnitus on patient functioning. (2019) (0)
ASCO 2001 Presidential address. (2001) (0)
Prevalence of hypogonadism in previously treated germ cell tumor patients. (2014) (0)
Evaluation and treatment of Hodgkin's disease in the 70s. (1972) (0)
Salvage chemotherapy with high-dose carboplatin and etoposide (HDCE) with peripheral blood stem cell transplant (PBSCT) in patients with relapsed seminoma (2007) (0)
Surveillance after complete response in patients with metastatic non-seminomatous germ-cell tumor (NSGCT). (2021) (0)
Gemzar (Gemcitabine): How I Use It (1997) (0)
Primary Retroperitoneal Lymph Node Dissection for Stage II Seminoma: Is Surgery the New Path Forward? (2023) (0)
FP01.04 BTCRC LUN19-396: Adjuvant Chemotherapy Plus Atezolizumab in Stage IB-IIIA Resected NSCLC and Clearance of ctDNA (2021) (0)
A phase II trial evaluating the efficacy of cabozantinib in the treatment of patients with refractory germ-cell tumors (GCT). (2022) (0)
Present Status of Chemotherapy for Testicular Cancer (1988) (0)
Risk factors for renal failure (RF) during high-dose chemotherapy (HDCT) and outcomes for patients (pts) with relapsed germ-cell tumors (rGCT). (2019) (0)
A multi-institutional experience with a brief course of aggressive chemotherapy in the extragonodal germ cell tumors (EGGCT). An SECSG study (1985) (0)
Evaluation and treatment of Hodgkin's disease in the 70's. (1975) (0)
Longitudinal evaluation of plasma miR371 to detect minimal residual disease and early relapse of germ cell tumors. (2023) (0)
Clinical Presentation and Diagnosis of Mediastinal Germ Cell Neoplasms (2018) (0)
Contents, Vol. 46, 1989 (1989) (0)
Phase II Trial of High‐Dose Cisplatin plus Etoposide plus Vinblastine in Non‐Small-Cell Lung Cancer (1991) (0)
NAD(P)H: Quinone oxidoreductase (NQO1) and catalase expression in nonseminomatous germ cell tumors. (2020) (0)
Chemotherapy of disseminated malignant melanoma with dimethyltriazeno imidazole carboxamide (DTIC) + methyl ccnu (MECCNU) + vincristine (VCR) (1977) (0)
Risk Factors for Acute Kidney Injury During High-dose Chemotherapy and Outcomes for Patients With Relapsed Germ Cell Tumors. (2020) (0)
Standard-dose salvage chemotherapy in patients with refractory metastatic germ-cell tumors (mGCT) progressing after high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT). (2020) (0)
OP3-10 IMPACT OF BLEOMYCIN ON RETROPERITONEAL HISTOLOGY AT POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION (PC-RPLND) IN GOOD RISK GERM CELL TUMORS (2014) (0)
High-dose chemotherapy (HDCT) and peripheral-blood stem cell transplant (PBSCT) in patients age 40 or older with relapsed metastatic germ-cell tumors (mGCT). (2020) (0)
Building a model to predict the risk of multiple severe neurotoxicities in cancer survivors after cisplatin treatment. (2022) (0)
Management of Residual Nonretroperitoneal Disease in Postchemotherapy Nonseminomatous Germ-Cell Tumors. (2023) (0)
Mediastinal germ cell tumors. (2007) (0)
A review of small cell lung cancer: diagnosis and treatment. (1980) (0)
A science for shrinking seminoma? (I: Reply) (1990) (0)
Chemotherapy of Testis Cancer (1983) (0)
Survival and toxicity outcomes in patients age 40 or older with relapsed metastatic germ cell tumors (mGCT) treated with high-dose chemotherapy (HDCT) and autologous peripheral-blood stem cell transplant (PBSCT). (2019) (0)
Combination chemotherapy with CCNU (NSC-79037) and 5-(3, 3-bis(2-chloroethyl)-1-triazeno)-imidazole-4-carboxamide (NSC-82196). (1975) (0)
Impact of adverse health outcomes (AHOs) on self-reported physical and mental health in U.S. testicular cancer survivors (TCS). (2022) (0)
Factors associated with use of medications for anxiety and depression in testicular cancer survivors after cisplatin-based chemotherapy. (2021) (0)
Tribute to John P. Donohue (1930–2008): The Best and the Brightest (2009) (0)
Medical centers: source for training future oncologists. (1985) (0)
Delayed toxicity of whole brain radiotherapy (WBRT) in germ cell tumor (GCT) patients with central nervous system (CNS) metastases (2007) (0)
PD53-02 ONCOLOGIC EFFICACY OF PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION FOR PATIENTS WITH PATHOLOGIC N1, N2, AND N3 DISEASE (2021) (0)
Combination chemotherapy with cis diamminedichloplatinum (CPDD), vinblastine (VLB) and bleomycin (BLEO) in disseminated testicular cancer (1976) (0)
PD51-02 ONCOLOGIC OUTCOMES OF PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION FOR STAGE II SEMINOMA: INDIANA UNIVERSITY EXPERIENCE (2022) (0)
813PDBRAIN METASTASES IN MALE GERM CELL TUMORS (GCT): A LARGE RETROSPECTIVE ANALYSIS ON BEHALF OF THE SWENOTECA AND THE G3 CONSORTIUM. (2014) (0)
NEZVYâAJNPRÍPAD DLHODOBÉHO PREÎÍVANIA PACIENTKY S CHEMOREFRAKTÉRNYM MERKELOVYM KARCINÓMOM UNUSUAL CASE OF LONG-TERM SURVIVAL OF THE PATIENT WITH CHEMOREFRACTORY MERKEL CELL CARCINOMA (2007) (0)
206 – Testicular Cancer (2012) (0)
Total-body irradiation with 25-MV photons in advanced non-Hodgkin's lymphoma and chronic lymphocytic leukemia. [Complications following therapy with 25 MV photons or /sup 60/Co. gamma. rays] (1978) (0)
Survival of good-risk germ cell tumor patients following post-chemotherapy retroperitoneal lymph node dissection: The effect of bleomycin during induction chemotherapy. (2014) (0)
The prognostic value of teratoma in the primary tumor and postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) specimens in patients with germ cell tumors (GCTs). (2018) (0)
Primary mediastinal seminoma: Treatment and survival outcomes. (2023) (0)
Prognosis and Surveillance of Mediastinal Germ Cell Tumors (2018) (0)
PET scan’s clinical utility in detecting residual disease in postchemotherapy germ cell cancer patients (2005) (0)
Combination chemotherapy with 5 day continuous infusion 5 fluorouracil (5 FU) and methyl CCNU in disseminated enteric adenocarcinoma (1975) (0)
Two Cycles of High Dose Chemotherapy with Autologous Bone Marrow Support for Patients with Locally Advanced Breast Cancer (1995) (0)
Surgical and oncologic outcomes of surgery in early metastatic seminoma: Multi-institutional retrospective study (2023) (0)
MP50-08 POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION (PC-RPLND) FOR SEMINOMA: IS SURGERY EFFECTIVE? (2023) (0)
PD51-01 CONTEMPORARY SURGICAL OUTCOMES OF RETROPERITONEAL LYMPH NODE DISSECTION FROM THE SEMS TRIAL (2022) (0)
Reply by Authors. (2020) (0)
Relations of perceived injustice to psycho‐spiritual outcomes in advanced lung and prostate cancer: Examining the role of acceptance and meaning making (2022) (0)
High-dose chemotherapy for relapsed testicular germ cell tumours (2022) (0)
Treatment of Multiply Recurrent Germ Cell Cancer (2003) (0)
had a duration of response of 7 years. This interesting article would suggest that there is a limited role for chemotherapy in selected patients with malignant transformation. (2003) (0)

This paper list is powered by the following services:

Other Resources About Lawrence Einhorn

What Schools Are Affiliated With Lawrence Einhorn?

Lawrence Einhorn is affiliated with the following schools: